Table 6.
A selection of clinically relevant drugs and compounds that are known Multidrug Resistance Protein 1 (MRP1)-substrates [55,68].
| Drugs Used in Oncology | Non-Oncological Drugs | |||
|---|---|---|---|---|
| Cytotoxic agents | Anthracyclines | doxorubicin, daunorubicin, epirubicin, idarubicin | Antibiotics | difloxacin grepafloxicin |
| Topoisomerase I inhibitors (campothecins) | irinotecan, topotecan | Metalloids | arsenite trivalent antimonite | |
| Topoisomerase II inhibitors (epipodophyllotoxins) | etoposide, teniposide | Peptides | glutathione | |
| Vinca-alkaloids | vincristine, vinblastine, vinorelbine, vindesine | Glutathione conjugates | cyclophosphamide-SG, doxorubicin-SG melphalan-SG, | |
| Antifolates | methotrexate | Sulfate conjugates | dehydroepiandrosterone-3-sulfate estrone-3-sulfate, | |
| Tyrosine kinase inhibitors | imatinib, gefitinib | Glucuronide conjugates | estradiol-17-β-D-glucuronide, etoposide-glucuronide, irinotecan-glucuronide, | |
| Folates | folic acid, L-leucovorin | |||